ライフサイエンスコーパス: convulxin

1 sure to platelet agonists (thrombin, ADP, or convulxin).

2 ype I collagen, collagen-related peptide, or convulxin.

3 R agonists SFLLRN and AYPGKF or GPVI agonist convulxin.

4 ollagen, collagen-related peptide (CRP), and convulxin.

5 high concentrations of thrombin, AYPGKF, or convulxin.

6 FcR gamma-chain and functional responses to convulxin.

7 ponse to high concentrations of collagen and convulxin.

8 e (PMA) and only slightly attenuated that by convulxin.

9 on stimulation with the snake C-type lectin, convulxin.

10 ly marginally inhibit aggregation induced by convulxin.

11 rylation and Ca(++) elevation in response to convulxin.

12 (U46619), and very low doses of thrombin and convulxin.

13 ADP, thromboxane analogue (U46619), TRAP, or convulxin.

14 ligand blotting using the snake venom toxin convulxin.

15 The addition of cathepsin G (425 nm) or convulxin (10 nm) to PRP dramatically reduced the t(50)

16 s strong adhesive and signaling responses to convulxin (a snake venom protein that directly binds GPV

17 Rap1 is robustly activated upon addition of convulxin, a GPVI-specific agonist.

18 in response to type I fibrillar collagen or convulxin, a snake venom protein and known platelet agon

19 ous activation with 2 agonists, thrombin and convulxin, an activator of the collagen receptor glycopr

20 coprotein (GP)VI-selective snake venom toxin convulxin and by collagen.

21 The GPVI-specific agonists convulxin and collagen-related peptide (CRP) also stimul

22 gregation using the GPVI-selective agonists, convulxin and collagen-related peptide (CRP) as well as

23 to initiate signalling events in response to convulxin and collagen-related peptide.

24 e cluster ligands in a manner reminiscent of convulxin and flavocetin.

25 imulation with the collagen receptor agonist convulxin and thrombin, 68% of platelets from C57BL/6 mi

26 f the total population and is referred to as convulxin and thrombin-induced-FV (COAT-FV) platelets.

27 co-injection of the glycoprotein VI agonist convulxin and was mimicked by glycoprotein VI inhibition

28 e, thrombin, PAR1-agonist, PAR4-agonist, and convulxin) and micro-ELISA arrays were used to quantify

29 )) mice were activated with the GPVI agonist convulxin, and surface expression of P-selectin (a marke

30 gonist thrombin, the glycoprotein VI agonist convulxin, and the cytokine receptor Mpl agonist thrombo

31 ivation induced by adenosine 5'-diphosphate, convulxin, and thrombin; (3) significant increases of pr

32 Notably, aegyptin prevents collagen but not convulxin binding to recombinant glycoprotein VI.

33 osphorylated proteins in response to TPO and convulxin but not by thrombin occurred with a similar ti

34 iate functional responses to the snake venom convulxin by reconstitution of mutant forms of GPVI in R

35 d with a number of agonists (TRAP, thrombin, convulxin, collagen, PMA, thapsigargin, or A23187) and a

36 50 = 6.7 muM), CRP-XL (IC50 = 53.5 muM), and convulxin (CVX) (IC50 = 5.7 muM) mediated platelet aggre

37 Convulxin (CVX) is a C-type lectin-like protein from the

38 Convulxin (CVX), a C-type snake protein from Crotalus du

39 t reactivity to adenosine diphosphate (ADP), convulxin (CVX), and thrombin receptor activator peptide

40 ide (CRP), and the snake venom C-type lectin convulxin (CVX).

41 23187 in conjunction with either thrombin or convulxin did generate this population.

42 Convulxin did not stimulate procoagulant activity in eit

43 ein kinase C further reduced the response to convulxin in pearl platelets demonstrating a direct role

44 Convulxin induced surface expression of P-selectin in SL

45 gamma null mice, for which collagen, but not convulxin, induced procoagulant activity (P <.01).

46 The convulxin-induced decrease was sensitive to both PKCalph

47 In contrast, convulxin-induced dense granule secretion was potentiate

48 shifted the concentration-response curve of convulxin-induced platelet aggregation to the right.

49 In PKC-delta-null murine platelets, convulxin-induced SHIP-1 phosphorylation was inhibited.

50 Consistent with the latter finding, convulxin-induced Syk phosphorylation is significantly a

51 MS16 also inhibits collagen-induced, but not convulxin-induced, platelet cytosolic Ca(2+) mobilizatio

52 her hand, activation of ERK2 by thrombin and convulxin is delayed and also inhibited by the protein k

53 e whether the weak inhibitory action against convulxin is due to release of agonists other than ADP f

54 Importantly, convulxin is not able to activate cells transfected with

55 methyl-BAPTA resulted in total inhibition of convulxin-mediated aggregation.

56 e to collagen or GPVI-specific agonists like convulxin or collagen-related peptide (CRP).

57 telets after costimulation with thrombin and convulxin (P <.05).

58 became "coated" after dual stimulation with convulxin plus thrombin (P < .05 vs C57BL/6 platelets).

59 rface following dual-agonist activation with convulxin plus thrombin to produce coated platelets.

60 ithout affecting aggregation induced by ADP, convulxin, PMA, and ristocetin.

61 antibody and by GP VI ligands (collagen and convulxin) reduced binding of biotinylated convulxin to

62 th thrombin plus the glycoprotein VI agonist convulxin resulted in a rapid loss of mitochondrial tran

63 that stimulation of platelets with thrombin/convulxin significantly increased the plasminogen signal

64 The Arf6-GTP decrease in convulxin-stimulated platelets showed similar requiremen

65 mong the proteins tyrosine phosphorylated on convulxin stimulation in PMA-differentiated HEL cells.

66 cellular Ca2+ in response to the snake venom convulxin that targets GPVI.

67 pairwise combinations of six agonists (ADP, convulxin, thrombin, U46619, iloprost and GSNO used at 0

68 but enhances, caspase-dependent PS exposure; convulxin-/thrombin-induced PS exposure is entirely depe

69 creases of procoagulant platelets induced by convulxin/thrombin and platelet-dependent thrombin gener

70 re induced by the Ca(2+)-mobilizing agonists convulxin/thrombin fully relied on mitochondrial depolar

71 to pairwise combinations of ADP, U46619, and convulxin to activate the P2Y(1)/P2Y(12), TP, and GPVI r

72 d convulxin) reduced binding of biotinylated convulxin to the stimulated platelets.

73 eated plasma to six different agonists (ADP, convulxin, U46619, SFLLRN, AYPGKF and PGE(2)) at three c

74 (BAPTA-AM) abolished aggregation induced by convulxin under all conditions.

75 ation induced by threshold concentrations of convulxin undergoes synergy with ADP acting via the P2Y1

76 uction by dual stimulation with thrombin and convulxin was less than that observed with A23187, indic

77 greater reduction in aggregation induced by convulxin was observed in pearl platelets than in the pr

78 Activation of phospholipase C by convulxin was potentiated by ADP acting through the P2Y1

79 elet aggregation at higher concentrations of convulxin was unaffected by these agents.

80 agonists collagen-related peptide (CRP) and convulxin were significantly inhibited in RhoG-deficient

81 ightly to the right at low concentrations of convulxin, whereas platelet aggregation at higher concen

82 are required for full aggregation induced by convulxin, whereas the response induced by collagen show

83 Strong agonists such as convulxin, which acts on GPVI, and thrombin cause sustai